Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch from dolutegravir/abacavir/lamivudine to bictegravir/emtricitabine/tenofovir alafenamide for neuropsychiatric outcomes in virologically suppressed adults with HIV-1
2018-004885-32Phase 3Completed
- Sponsor
- Azienda Ospedaliera Universitaria Senese
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of bictegravir, emtricitabine, tenofovir alafenamide, dolutegravir, abacavir and 1 more in Human immunodeficiency virus infection type 1 (2 arms), sponsored by Azienda Ospedaliera Universitaria Senese. Started May 2021; status: completed.
02
Drugs
bictegraviremtricitabinetenofovir alafenamidedolutegravirabacavir
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2018-004885-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004885-32.